InvestorsHub Logo
Followers 19
Posts 2315
Boards Moderated 0
Alias Born 03/12/2013

Re: guardiangel post# 24151

Monday, 07/21/2014 2:19:26 PM

Monday, July 21, 2014 2:19:26 PM

Post# of 30046
It was early October 2010 that William signed a non compete agreement and the use of DR-70 back in October 2010.... So William used Provista Life Sciences..That means the agreement was between William/ PLS L.L.C./ now known as Memory LLC and Radient/AMDL Inc...William is obligated by the agreement personally and through his Memory/Provista Life Sciences, This concurs that William cannot use DR-70 at will until his 5 year non compete and the use of Radients's DR-70 until October 2015...Wolf

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

News | October 14, 2010
Radient Pharmaceuticals And Provista Life Sciences Announce New Blood Test For Lung Cancer
LC04.jpg

Tustin, CA (Marketwire) - Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the validation study results of a blood test for early detection of lung cancer and Provista's plans to broadly introduce this new test to market.

The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.